Newron Pharmaceuticals S.p.A. (SWX:NWRN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 192.42M -32.4% |
| Revenue (ttm) | 9.62M -82.6% |
| Net Income | -27.27M |
| EPS | -1.35 |
| Shares Out | 21.24M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,442 |
| Open | 9.20 |
| Previous Close | 9.00 |
| Day's Range | 8.92 - 9.20 |
| 52-Week Range | 5.72 - 31.85 |
| Beta | 0.84 |
| Analysts | Strong Buy |
| Price Target | 37.71 (+316.23%) |
| Est. Earnings | Dec 23, 2026 |
About Newron Pharmaceuticals
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III cl... [Read more]
Analyst Summary
According to 3 analysts, the average rating for NWRN stock is "Strong Buy." The 12-month stock price target is CHF 37.71, which is an increase of 316.23% from the latest price.
News
Newron Pharmaceuticals Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
Three pivotal readouts are expected in 2027 for evenamide in TRS, with ENIGMA-TRS 1 results beginning in Q1. FDA discussions continue on U.S. participation in ENIGMA-TRS 2 after a death prompted a clinical hold at U.S. sites.
Newron Pharma price target lowered to CHF 30 from CHF 44 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Newron Pharma (NWPHF) to CHF 30 from CHF 44 and keeps a Buy rating on the shares. The firm says evenamide remains…
Newron Pharmaceuticals Transcript: Investor update
FDA feedback prompted broader cardiac review and proposed screening safeguards for ENIGMA-TRS 2, while non-U.S. enrollment continues. ENIGMA-TRS 1 had 514 patients randomized, with 12-week results expected in Q1 2027; funding extends through most of 2027.
Newron Pharmaceuticals Press release: Investor update
Newron Pharmaceuticals issued a press release on October 8, 2026, disclosing material business information to investors.
Newron Pharma price target lowered to CHF 19 from CHF 35 at Roth Capital
Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on Newron Pharma (NWPHF) to CHF 19 from CHF 35 and keeps a Buy rating on the shares. The firm…
Newron Pharmaceuticals Earnings release: H1 2026
Newron Pharmaceuticals released its H1 2026 earnings on September 22, 2026, summarizing the period's financial results.
Newron Pharmaceuticals Quarterly report: H1 2026
Newron Pharmaceuticals has published its H1 2026 quarterly earnings report on September 22, 2026.
Newron Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference
A novel glutamate modulator for schizophrenia is advancing through two pivotal phase III trials, targeting a large unmet need with strong efficacy, safety, and IP protection. Key results are expected in 2027, with significant commercial and regulatory momentum.
Newron Provides Update Following Type A Meeting With the FDA
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with...
Newron Pharmaceuticals to Participate in June Investor Conferences
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #Biotech--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapie...
Newron Pharma price target lowered to CHF 44 from CHF 48 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Newron Pharma (NWPHF) to CHF 44 from CHF 48 and keeps a Buy rating on the shares.
Newron Pharma price target raised to CHF 48 from CHF 43 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Newron Pharma (NWPHF) to CHF 48 from CHF 43 and keeps a Buy rating on the shares. The firm…
Newron Pharmaceuticals Transcript: 38th Annual Roth Conference
A novel add-on therapy for treatment-resistant schizophrenia is advancing through three pivotal global studies, showing sustained efficacy and a unique mechanism targeting hippocampal hyperexcitability. Regulatory submission is expected within 12–15 months, with strong physician interest and no direct competition in its segment.
Newron Pharmaceuticals Earnings Call Transcript: H2 2025
Achieved major milestones with pivotal phase III studies for evenamide, strong financial position, and new IP protection. Results expected by end of 2026 will support NDA submission, with additional funding and NASDAQ uplisting preparations underway.
Newron Pharmaceuticals Annual report: H2 2025
Newron Pharmaceuticals has published its H2 2025 annual report on March 24, 2026.
Newron Pharmaceuticals Slides: H2 2025
Newron Pharmaceuticals has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 24, 2026.
Newron Pharmaceuticals Earnings release: H2 2025
Newron Pharmaceuticals released its H2 2025 earnings on March 24, 2026, summarizing the period's financial results.
Newron Presents 2025 Financial Results and Provides 2026 Outlook
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron today announced its financial results and operational highlights for the business year ended Dec. 31, 2025, and provided an o...
Newron to Present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel th...
Newron Announces Agreement With the European Investment Bank (EIB) to Extend the Near-Term Tranche Repayment Dates of Its 2018 Finance Contract
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 Finan...
Newron Announces Nominations to Its Board of Directors at Upcoming Annual General Meeting
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron announces nominations to its Board of Directors at its upcoming Annual General Meeting.
Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program
MILAN, Italy & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron secures up to EUR 38 million to advance Phase III Evenamide program as potential first add-on therapy for treatment-re...
Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron Pharmaceuticals notes new publication highlighting clinically meaningful benefits of evenamide as an adjunctive treatment in ...
Newron Pharma price target raised to CHF 43 from CHF 26 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Newron Pharma (NWPHF) to CHF 43 from CHF 26 and keeps a Buy rating on the shares. The firm…
EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron's partner EA Pharma Co., Ltd. announces today the initiation of its Phase III clinical trial with evenamide in Japan.